Quarterly report pursuant to Section 13 or 15(d)

Development Awards and Deferred Revenue (Details Narrative)

v3.20.2
Development Awards and Deferred Revenue (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Jan. 26, 2018
Jul. 31, 2020
Jun. 30, 2020
May 31, 2019
Mar. 31, 2019
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Dec. 31, 2019
Dec. 31, 2018
Development Award [Line Items]                      
Revenue recognized               $ (2,048,405)      
Revenue           $ 286,346 $ 29,094,583 $ 2,048,405 $ 30,980,265    
CFF Warrant [Member]                      
Development Award [Line Items]                      
Warrant exercisable price per share     $ 13.20     $ 13.20   $ 13.20      
Cystic Fibrosis Foundation [Member]                      
Development Award [Line Items]                      
Payments for royalty       $ 2,700,000              
Cystic Fibrosis Foundation [Member] | Subsequent Event [Member]                      
Development Award [Line Items]                      
Payments for milestone achievement   $ 5,000,000                  
Collaboration and License Agreement [Member] | Kaken Pharmaceutical Co., Ltd. [Member]                      
Development Award [Line Items]                      
Upfront payment, received from related party         $ 27,000,000            
Consideration receivable on milestone payments         $ 173,000,000            
Royalty term description         The period beginning on the date of the first commercial sale of the Licensed Product in Japan and ends on the latest of (i) the expiration of the last valid claim of the royalty patents covering such Licensed Product in Japan, (ii) the expiration of regulatory exclusivity for such Licensed Product for such Initial Indication in Japan, or (iii) ten (10) years after the first commercial sale of such Licensed Product for such Initial Indication in Japan. The Agreement may be terminated by either party for material breach, upon a party's insolvency or bankruptcy or upon a challenge by one party of any patents of the other party, and Kaken may terminate in specified situations, including for a safety concern or clinical failure, or at its convenience following the second anniversary of the first commercial sale of a Licensed Product in either of the Initial Indications in the Territory, with 180 days' notice.            
Revenue from related parties, recorded as deferred revenue         $ 27,000,000            
Revenue recognized             27,000,000        
Royalty payable       $ 27,000,000     27,000,000   27,000,000    
Cystic Fibrosis Program Related Investment Agreement [Member] | Phase 2b Clinical Trial [Member]                      
Development Award [Line Items]                      
Proceeds from investments on achieving milestones                 17,500,000    
Cystic Fibrosis Program Related Investment Agreement [Member] | Maximum [Member]                      
Development Award [Line Items]                      
Development award received $ 25,000,000                    
Investment Agreement [Member]                      
Development Award [Line Items]                      
Payment of milestone related received     $ 5,000,000                
Revenue               $ 5,000,000   $ 5,000,000 $ 12,500,000
Investment Agreement [Member] | Subsequent Event [Member]                      
Development Award [Line Items]                      
Revenue   $ 22,500,000                  
Investment Agreement [Member] | Cystic Fibrosis Foundation Warrants [Member]                      
Development Award [Line Items]                      
Revenue               25,000,000      
Additional paid in capital, fair value of warrant issued               6,215,225      
Revenue to be recognized     $ 18,784,775     $ 18,784,775   $ 18,784,775      
Research and development period               2 years 9 months      
Collaboration Agreement [Member] | Cystic Fibrosis Foundation [Member]                      
Development Award [Line Items]                      
Royalty payment percentage 10.00%                    
Investment Agreement [Member] | 2018 CFF Award [Member]                      
Development Award [Line Items]                      
Revenue           $ 286,346 $ 2,094,583 $ 2,048,405 $ 3,980,265    
Investment Agreement [Member] | CFF Warrant [Member]                      
Development Award [Line Items]                      
Warrant to purchase of common stock     1,000,000     1,000,000   1,000,000      
Warrant exercisable price per share     $ 13.20     $ 13.20   $ 13.20      
Warrants expiration term     Jan. 26, 2025     Jan. 26, 2025   Jan. 26, 2025      
Investment Agreement [Member] | CFF Warrant [Member] | Immediately Exercisable Warrants [Member]                      
Development Award [Line Items]                      
Warrant to purchase of common stock     500,000     500,000   500,000      
Investment Agreement [Member] | CFF Warrant [Member] | Warrants Exercisable On Completion Of Final Milestone [Member]                      
Development Award [Line Items]                      
Warrant to purchase of common stock     500,000     500,000   500,000